JP2010240078A - 腫瘍自動識別装置及び腫瘍部位の自動識別方法 - Google Patents
腫瘍自動識別装置及び腫瘍部位の自動識別方法 Download PDFInfo
- Publication number
- JP2010240078A JP2010240078A JP2009090541A JP2009090541A JP2010240078A JP 2010240078 A JP2010240078 A JP 2010240078A JP 2009090541 A JP2009090541 A JP 2009090541A JP 2009090541 A JP2009090541 A JP 2009090541A JP 2010240078 A JP2010240078 A JP 2010240078A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- wavelength
- ppix
- fluorescence
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 133
- 238000012850 discrimination method Methods 0.000 title 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims abstract description 68
- 238000001514 detection method Methods 0.000 claims abstract description 66
- 229950003776 protoporphyrin Drugs 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 39
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 11
- 230000005284 excitation Effects 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000013307 optical fiber Substances 0.000 claims description 18
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 11
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 11
- 239000004065 semiconductor Substances 0.000 claims description 8
- 230000001678 irradiating effect Effects 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 6
- 230000003595 spectral effect Effects 0.000 abstract description 11
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 31
- 201000011510 cancer Diseases 0.000 description 14
- 206010018338 Glioma Diseases 0.000 description 11
- 238000002189 fluorescence spectrum Methods 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000005017 glioblastoma Diseases 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000032612 Glial tumor Diseases 0.000 description 8
- 238000005286 illumination Methods 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 6
- 238000002428 photodynamic therapy Methods 0.000 description 6
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- -1 n-propanoyl Chemical group 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 244000172533 Viola sororia Species 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 125000004492 methyl ester group Chemical group 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000002165 photosensitisation Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000005811 Viola adunca Nutrition 0.000 description 2
- 240000009038 Viola odorata Species 0.000 description 2
- 235000013487 Viola odorata Nutrition 0.000 description 2
- 235000002254 Viola papilionacea Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007428 craniotomy Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229950010481 5-aminolevulinic acid hydrochloride Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010036193 Porphyrinuria Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Landscapes
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
【解決手段】被検体に投与された5‐ALAから誘導されたプロトポルフィリン(PpIX)が励起された場合に発する蛍光を分光検出することにより正常部位と腫瘍部位とを自動的に識別する。腫瘍部に蓄積されたPpIXを励起させるために励起光を照射する励起工程と、前記励起光によって励起されたPpIXが発する蛍光を受光する受光工程と、受光した蛍光を分光することにより得られる波長636±2nmと波長626±2nmにおける相対蛍光強度を検出する分光検出工程と、波長636±2nmと波長626±2nmにおける相対蛍光強度の差が設定値以上である場合に、報知する検知音を出力する報音工程とを備える。
【選択図】図2
Description
図2に示される本発明の腫瘍自動識別装置を用いた。まず、腫瘍摘出手術の3時間前に、50mLの5%グルコース溶液に溶解した20mg/kgの5‐アミノレブリン酸塩酸塩(5‐ALA・塩酸)を悪性脳腫瘍患者に経口投与した。開頭後、グリオーマ病変部位(直径50mm)に光源用細径光ファイバーを医療技術者が操作して、紫色半導体レーザー(波長405nmのレーザー光、照射パワー140mW、シャープカットオフフィルター使用)照射を実施した。結果を図3に示す。図3中、Aは直径20mmの壊死部分、Bは直径24mmのグリオブラストーマ部分、Cは直径30mmの腫瘍細胞が正常細胞に浸潤している部分、Dは直径35mmの腫瘍細胞が正常細胞に一部浸潤している部分、Eは正常細胞部分を示す。また、図5は、かかるグリオーマ病変部位(組織像)と対応するPCの蛍光スペクトル画面を表す。施術に際して、報音手段であるPCから、Aの壊死部分やEの正常細胞部分では検知音の出力はなく、Bのグリオブラストーマ部分からは比較的大きい音量あるいは比較的短い断続周期あるいは比較的高い周波数の検知音が、Cの腫瘍が正常組織に浸潤している部分からはやや大きい音量あるいはやや短い断続周期あるいは中程度の周波数の検知音が、Dの腫瘍が正常組織に一部浸潤している部分からは通常の音量あるいは比較的長い断続周期あるいは比較的低い周波数の検知音がそれぞれ出力され、蛍光スペクトル画面を見ることなく、執刀医はグリオーマ病変部位を目視観察しながら報音により腫瘍部位を摘出することができる。
Claims (9)
- 被検体に投与された腫瘍検出剤から誘導されたプロトポルフィリンIX(PpIX)が励起された場合に発する蛍光を分光検出することにより正常部位と腫瘍部位を自動的に識別しうる装置であって、
腫瘍部に蓄積されたPpIXを励起させるために励起光を導光照射する光源用細径光ファイバーと、
該光源用細径光ファイバーと一体化され、前記励起光によって励起されたPpIXが発する蛍光を受光し、分光器に導光する計測用細径光ファイバーと、
分光器に導光された蛍光を分光することにより得られる波長636±2nmと波長626±2nmにおける相対蛍光強度を検出する分光検出手段と、
波長636±2nmと波長626±2nmにおける相対蛍光強度の差が設定値以上である場合に、報知する検知音を出力する報音手段と、
を備えた腫瘍自動識別装置。 - 光源用細径光ファイバーが、波長405±5nmの紫色半導体レーザーを励起光源とすることを特徴とする請求項1記載の腫瘍自動識別装置。
- 分光検出手段が、さらに、部分的に開環したPpIXの670±2nmの波長における相対蛍光強度を検出する手段を備えていることを特徴とする請求項1又は2記載の腫瘍自動識別装置。
- 報音手段が、波長636±2nmと波長626±2nmにおける相対蛍光強度の差の大小により、出力する検知音の周波数又は強弱が変化することを特徴とする請求項1〜3のいずれか記載の腫瘍自動識別装置。
- 被検体に投与された腫瘍検出剤から誘導されたプロトポルフィリンIX(PpIX)が励起された場合に発する蛍光を分光検出することにより正常部位と腫瘍部位とを自動的に識別する方法であって、
腫瘍部に蓄積されたPpIXを励起させるために励起光を照射する励起工程と、
前記励起光によって励起されたPpIXが発する蛍光を受光する受光工程と、
受光した蛍光を分光することにより得られる波長636±2nmと波長626±2nmにおける相対蛍光強度を検出する分光検出工程と、
波長636±2nmと波長626±2nmにおける相対蛍光強度の差が設定値以上である場合に、報知する検知音を出力する報音工程と、
を備えた腫瘍部位の自動識別方法。 - 腫瘍検出剤が5‐アミノレブリン酸であることを特徴とする請求項5記載の腫瘍部位の自動識別方法。
- 腫瘍部が、悪性脳腫瘍部であることを特徴とする請求項5又は6記載の腫瘍部位の自動識別方法。
- さらに、部分的に開環したPpIXの670±2nmの波長における相対蛍光強度を検出する工程を備えていることを特徴とする請求項5〜7のいずれか記載の腫瘍部位の自動識別方法。
- 報音工程において、波長636±2nmと波長626±2nmにおける相対蛍光強度の差の大小により、出力する検知音の周波数又は強弱が変化することを特徴とする請求項5〜8のいずれか記載の腫瘍部位の自動識別方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009090541A JP5467632B2 (ja) | 2009-04-02 | 2009-04-02 | 腫瘍自動識別装置及び腫瘍部位の自動識別方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009090541A JP5467632B2 (ja) | 2009-04-02 | 2009-04-02 | 腫瘍自動識別装置及び腫瘍部位の自動識別方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010240078A true JP2010240078A (ja) | 2010-10-28 |
JP5467632B2 JP5467632B2 (ja) | 2014-04-09 |
Family
ID=43093863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009090541A Active JP5467632B2 (ja) | 2009-04-02 | 2009-04-02 | 腫瘍自動識別装置及び腫瘍部位の自動識別方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5467632B2 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013002350A1 (ja) * | 2011-06-29 | 2013-01-03 | 京都府公立大学法人 | 腫瘍部位の識別装置及び識別方法 |
WO2014030344A1 (ja) | 2012-08-23 | 2014-02-27 | Sbiファーマ株式会社 | コリメータを備えた光線力学的診断装置 |
EP2835094A4 (en) * | 2012-04-05 | 2016-03-09 | Sbi Pharmaceuticals Co Ltd | DEVICE FOR DETERMINING THE METASTASIS OF CANCER IN A SENTINEL GANGLION |
WO2016063945A1 (ja) * | 2014-10-24 | 2016-04-28 | 京都府公立大学法人 | 腫瘍部位の判別方法、腫瘍部位の判別装置 |
JP2016132658A (ja) * | 2015-01-22 | 2016-07-25 | Sbiファーマ株式会社 | 悪性中皮腫の診断補助方法及び診断補助剤 |
KR101807392B1 (ko) * | 2016-03-10 | 2017-12-12 | 연세대학교 산학협력단 | 자기공명 이미지에서 조영 증강이 없는 뇌실벽에서 수술 중 광감작제-유도 형광에 의한 신경교종 탐지 |
JP2019534057A (ja) * | 2016-09-15 | 2019-11-28 | アヴェント インコーポレイテッド | 標的指向性にされた蛍光分子を用いる神経のその場での視覚化のためのシステムおよび方法 |
WO2024005178A1 (ja) * | 2022-07-01 | 2024-01-04 | ネオファーマジャパン株式会社 | 安定性に優れた非水性製剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS649345A (en) * | 1987-06-30 | 1989-01-12 | Shimadzu Corp | Method of analyzing porphyrins |
WO2009003173A1 (en) * | 2007-06-27 | 2008-12-31 | The General Hospital Corporation | Method and apparatus for optical inhibition of photodymanic therapy |
JP2009148568A (ja) * | 2007-12-19 | 2009-07-09 | Kantonsspital Aarau Ag | 蛍光画像の分析処理方法 |
-
2009
- 2009-04-02 JP JP2009090541A patent/JP5467632B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS649345A (en) * | 1987-06-30 | 1989-01-12 | Shimadzu Corp | Method of analyzing porphyrins |
WO2009003173A1 (en) * | 2007-06-27 | 2008-12-31 | The General Hospital Corporation | Method and apparatus for optical inhibition of photodymanic therapy |
JP2009148568A (ja) * | 2007-12-19 | 2009-07-09 | Kantonsspital Aarau Ag | 蛍光画像の分析処理方法 |
Non-Patent Citations (2)
Title |
---|
JPN6013056245; Ekaterina Borisova et al.: '"5-ALA Mediated Fluorescence Detection of Gastroin' Advances in Optical Technologies Vol.2008 , pp.1-7 * |
JPN6013056247; 三好 憲雄 他: '"5-Aminolevulinic Acid(5-ALA)を投与した腫瘍内代謝物Protoporph' 日本レーザー医学会誌 第23巻 第3号 , 2002, 81〜88頁 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9241636B2 (en) | 2011-06-29 | 2016-01-26 | Kyoto Prefectural Public University Corporation | Tumor site or parathyroid gland identification device and method |
CN103608662A (zh) * | 2011-06-29 | 2014-02-26 | 京都府公立大学法人 | 肿瘤部位的识别装置以及识别方法 |
CN103608662B (zh) * | 2011-06-29 | 2016-09-28 | 京都府公立大学法人 | 肿瘤部位的识别装置以及识别方法 |
JPWO2013002350A1 (ja) * | 2011-06-29 | 2015-02-23 | 京都府公立大学法人 | 腫瘍部位の識別装置及び識別方法 |
EP2728344A4 (en) * | 2011-06-29 | 2015-04-08 | Kyoto Prefectural Public Univ Corp | DEVICE AND METHOD FOR IDENTIFYING THE SITE OF A TUMOR |
WO2013002350A1 (ja) * | 2011-06-29 | 2013-01-03 | 京都府公立大学法人 | 腫瘍部位の識別装置及び識別方法 |
EP2835094A4 (en) * | 2012-04-05 | 2016-03-09 | Sbi Pharmaceuticals Co Ltd | DEVICE FOR DETERMINING THE METASTASIS OF CANCER IN A SENTINEL GANGLION |
US20150238085A1 (en) * | 2012-08-23 | 2015-08-27 | Sbi Pharmaceuticals Co., Ltd. | Photodynamic diagnosis apparatus provided with collimator |
CN104519782A (zh) * | 2012-08-23 | 2015-04-15 | 思佰益药业股份有限公司 | 具备准直器的光动力学诊断装置 |
EP2888988A4 (en) * | 2012-08-23 | 2016-06-15 | Sbi Pharmaceuticals Co Ltd | PHOTODYNAMIC DIAGNOSTIC APPARATUS WITH COLLIMATOR |
JPWO2014030344A1 (ja) * | 2012-08-23 | 2016-07-28 | Sbiファーマ株式会社 | コリメータを備えた光線力学的診断装置 |
WO2014030344A1 (ja) | 2012-08-23 | 2014-02-27 | Sbiファーマ株式会社 | コリメータを備えた光線力学的診断装置 |
JP2018057877A (ja) * | 2012-08-23 | 2018-04-12 | Sbiファーマ株式会社 | コリメータを備えた光線力学的診断装置と蛍光診断モードを有する手術顕微鏡との組み合わせからなる術中診断システム |
WO2016063945A1 (ja) * | 2014-10-24 | 2016-04-28 | 京都府公立大学法人 | 腫瘍部位の判別方法、腫瘍部位の判別装置 |
JP2016085113A (ja) * | 2014-10-24 | 2016-05-19 | 京都府公立大学法人 | 腫瘍部位の判別方法、腫瘍部位の判別装置 |
JP2016132658A (ja) * | 2015-01-22 | 2016-07-25 | Sbiファーマ株式会社 | 悪性中皮腫の診断補助方法及び診断補助剤 |
KR101807392B1 (ko) * | 2016-03-10 | 2017-12-12 | 연세대학교 산학협력단 | 자기공명 이미지에서 조영 증강이 없는 뇌실벽에서 수술 중 광감작제-유도 형광에 의한 신경교종 탐지 |
JP2019534057A (ja) * | 2016-09-15 | 2019-11-28 | アヴェント インコーポレイテッド | 標的指向性にされた蛍光分子を用いる神経のその場での視覚化のためのシステムおよび方法 |
WO2024005178A1 (ja) * | 2022-07-01 | 2024-01-04 | ネオファーマジャパン株式会社 | 安定性に優れた非水性製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP5467632B2 (ja) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5467632B2 (ja) | 腫瘍自動識別装置及び腫瘍部位の自動識別方法 | |
JP6420446B2 (ja) | コリメータを備えた光線力学的診断装置と蛍光診断モードを有する手術顕微鏡との組み合わせからなる術中診断システム | |
US10488340B2 (en) | Imaging a target fluorophore in a biological material in the presence of autofluorescence | |
Wagnieres et al. | In vivo fluorescence spectroscopy and imaging for oncological applications | |
Hillemanns et al. | Photodetection of cervical intraepithelial neoplasia using 5‐aminolevulinic acid–induced porphyrin fluorescence | |
EP2793679B1 (en) | An illumination system for endoscopic applications | |
Pogue et al. | In Vivo NADH Fluorescence Monitoring as an Assay for Cellular Damage in Photodynamic Therapy¶ | |
Belykh et al. | Scanning fiber endoscope improves detection of 5-aminolevulinic acid–induced protoporphyrin IX fluorescence at the boundary of infiltrative glioma | |
WO2013002350A1 (ja) | 腫瘍部位の識別装置及び識別方法 | |
JP5889398B2 (ja) | センチネルリンパ節がん転移識別装置 | |
Loshchenov et al. | Laser-induced fluorescence diagnosis of stomach tumor | |
Chen et al. | Kinetics and subcellular localization of 5-ALA-induced PpIX in DHL cells via two-photon excitation fluorescence microscopy | |
Bae et al. | Multispectral autofluorescence imaging for detection of cervical lesions: a preclinical study | |
JP5883889B2 (ja) | 光線力学的診断剤、及び、フォトブリーチング防止剤 | |
Ohsaki et al. | Observation of Zn-photoprotoporphyrin red Autofluorescence in human bronchial cancer using color-fluorescence endoscopy | |
Geavlete et al. | Fluorescence cystoscopy | |
Krammer et al. | Basic principles | |
Jichlinski et al. | Georges Wagnières | |
Akimoto et al. | Rapid intraoperative detection of residual glioma cell in resection cavity walls using a compact fluorescence microscope | |
RU2395124C2 (ru) | Способ исследования биораспределения фотосенсибилизаторов | |
Jayachandran et al. | Autofluorescence and diffuse reflectance spectroscopic analysis of oral premalignancy and malignancy | |
Nadeau | Fluorescence imaging and spectroscopy systems for cancer diagnostics | |
Ho et al. | Photodynamic drug detection system for measurement of drug uptake | |
Jarvi | Evaluation of photophysical methods for photodynamic therapy dosimetry | |
Marcon | Fluorescence spectroscopy and imaging for detection of colonic dysplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140123 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140124 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5467632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |